Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. - Wikidata - awgldk - TriplyDB

Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study.

Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study.

http://www.wikidata.org/entity/Q37438706

about

The Relationship between NALP3 and Autoinflammatory Syndromes Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies Lighting the fires within: the cell biology of autoinflammatory diseases Beyond the NLRP3 inflammasome: autoinflammatory diseases reach adolescence Working the endless puzzle of hereditary autoinflammatory disorders.IL-1 blockade in autoinflammatory syndromes.An update on autoinflammatory diseases First report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS).Targeting the inflammasome in rheumatic diseases.Autoinflammatory syndromes Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling.New tricks from an old dog: mitochondrial redox signaling in cellular inflammation.Biological treatments: new weapons in the management of monogenic autoinflammatory disorders Monogenic autoinflammatory diseases: concept and clinical manifestations.The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases.Monogenic autoinflammatory diseases: disorders of amplified danger sensing and cytokine dysregulation.Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study.Recurrent fevers in children: TRAPS for young players.Monogenic autoinflammatory diseases.Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome.Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS).Recommendations for the management of autoinflammatory diseases.Immunotherapeutic Biologic Agents in Autoimmune and Autoinflammatory Diseases.Geoepidemiology and Immunologic Features of Autoinflammatory Diseases: a Comprehensive Review.A systematic approach to autoinflammatory syndromes: a spelling booklet for the beginner.A Comprehensive Overview of the Hereditary Periodic Fever Syndromes.Canakinumab for the treatment of TNF-receptor associated periodic syndrome.Off-label use of tumour necrosis factor-alpha inhibitors and anakinra at an Australian tertiary hospital.Systemic and organ involvement in monogenic autoinflammatory disorders: a global review filtered through internists' lens.An Update on the Use of Immunomodulators in Primary Immunodeficiencies.An Up-to-date Approach to a Patient with a Suspected Autoinflammatory Disease.Monogenic Periodic Fever Syndromes: Treatment Options for the Pediatric Patient.Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature.Autoinflammatory Diseases with Periodic Fevers.Modified regimen of etanercept for tumor necrosis factor receptor associated periodic syndrome (TRAPS) like illness.Tumor necrosis factor-associated periodic syndrome in adults.Biological therapies in monogenic autoinflammatory diseases: long-term efficacy and safety.A Case of Schnitzler's Syndrome without Monoclonal Gammopathy-Associated Chronic Urticaria Treated with Anakinra.Inositol-Requiring Enzyme 1-Mediated Downregulation of MicroRNA (miR)-146a and miR-155 in Primary Dermal Fibroblasts across Three TNFRSF1A Mutations Results in Hyperresponsiveness to Lipopolysaccharide.

P2860

Q26749025-FAFB0432-979A-4E1C-BC55-EF2E7636BBC1 Q26799747-78BE5FAB-57CD-4303-BD32-D5A3C4B1F1E1 Q26827163-01785D45-1721-43FB-8FA7-DC93F146F441 Q27011650-DFCA6F1A-6A69-4847-9EE1-87A11CD21E17 Q33357128-08E6368B-4BAB-49C7-A277-3DDB69166E58 Q34262561-1C312FCE-6FA4-432A-84D4-1567F16AE908 Q34380526-0D73BCB4-C289-4776-B39D-52A2A92D0AEC Q34997023-A8980D0C-A71A-4B18-BD17-28D3BF18B5BD Q35804717-70B1C328-5CC9-449F-88C6-B28F561D6AFE Q35810569-6F69021C-B31F-4C12-B650-E25D78C87240 Q36041225-9572A91B-E602-403C-84D3-2448EB5E0DF2 Q36834142-29E4B1E3-8B9A-40D2-A1C2-4034337060F8 Q37077564-EC81EF01-D783-44C0-902F-B1EA470B7858 Q37162157-BA034929-4E81-456C-A1F7-6EC61F3D92C0 Q37270409-5FFBCE70-CD82-45E2-B760-E6EBC7193E31 Q37466515-EBEB0F43-D512-4484-989E-D44E3955D679 Q37604504-0F52D45F-E12C-4B23-9F56-D41A2655284E Q37703762-CEDAD859-EB41-4989-B2C4-DB7A02D3396E Q38211947-DACD590B-89A7-46EC-9CAE-F749D3D5DC69 Q38220758-164FB06C-B671-4CE3-9F58-3740C59DC990 Q38517828-2C7970A7-B32E-4EB9-86E5-B70D82EC118C Q38537504-77C8052E-8760-4945-937D-85DAAF61CE10 Q38635412-74CAD618-8F5F-41E7-B09C-5F16E88B74C4 Q38746358-48BECE99-8EDC-4E49-883D-B1F64151BC8A Q38773387-D4791B41-0AB6-460E-B693-EE819C179942 Q38805718-5D1C94D4-222E-4C87-BBBA-AF670496C7DB Q38814103-0DE2F694-A1C3-4018-B064-3B762704ECA1 Q38826765-19F88453-9AC0-4F17-A943-AF4E061DF4D2 Q38843398-A7E3A806-AD07-489F-A5D6-6805BAE41CC0 Q39016299-881C82BD-3D27-4508-AB28-EF023E0AF89C Q39126636-4219F16A-C447-456F-AB6B-E2A111DD331C Q39301708-24D980A2-E8A4-4CE7-A68C-C1C0715E0398 Q39325689-5D1091EC-33EC-4249-BA0F-CA5A1D71EBDE Q39384980-50DC3744-BE4B-4524-A068-27F845D48A68 Q40217036-AFF5D37F-BF46-4F53-9381-4176CC14856F Q41929105-B66A1CAD-07E0-4A53-A00D-ADD1607A2AF6 Q46104569-B0CED537-8CF5-4D9E-88EC-22E6333A76A4 Q47133706-2E70EFF1-1D22-4C45-8959-72ACE278C959 Q50152542-AB590B30-06A6-4226-A6F6-4B2E23CD64D2

P2860

Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study.

http://www.wikidata.org/entity/Q37438706

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Efficacy of etanercept in the ...... -label, dose-escalation study.

@en

Efficacy of etanercept in the ...... -label, dose-escalation study.

@nl

type

label

Efficacy of etanercept in the ...... -label, dose-escalation study.

@en

Efficacy of etanercept in the ...... -label, dose-escalation study.

@nl

prefLabel

Efficacy of etanercept in the ...... -label, dose-escalation study.

@en

Efficacy of etanercept in the ...... -label, dose-escalation study.

@nl

P1433

Q37438706-A7D8DDE0-7881-4F60-B056-F31F2B8504CB

P1476

Q37438706-EC2076A0-5841-4D72-8222-8ECCC56F5607

P2093

Q37438706-187B87D8-2920-4632-A88C-639E4182EDFE

Q37438706-63289229-88B4-4C7A-B34B-C2E236B898AA

Q37438706-92BA78D5-C306-427D-A266-5ADE77A5460C

Q37438706-A375A1B9-A247-4FAF-B582-51ADF98E23E4

Q37438706-C206D7C7-4924-4C59-ADF5-A14E0DFD8D3E

Q37438706-D05D8169-D8EF-4FBA-A959-C778FE03D819

Q37438706-D24F7F82-F64D-4247-B699-8547989C47FD

Q37438706-D4B4B3C6-A083-4F1A-8597-C7EE3E2C1A7C

Q37438706-EBB48C39-7E78-429A-BFCF-911CD5EE6A56

Q37438706-FB614F72-175D-4836-9540-A23906346845

P2860

Q37438706-0734DA48-5E30-45D9-AA0C-6B996362E951

Q37438706-1C3E2529-3278-49B3-B3CD-5C55EE948162

Q37438706-1F064DAE-6FA7-4D10-8EBE-E6F6EBFC82CB

Q37438706-3B751297-C7BA-4073-A88A-FE51CE02852B

Q37438706-4B581C3A-D415-4DA5-A611-80170E8B0420

Q37438706-66E4FBA8-71D8-483B-9869-6F95A9C3631C

Q37438706-746713B4-92C5-4630-8AD6-3CDC644651A1

Q37438706-75A563EC-AD84-463A-8462-DB6E9CE38C70

Q37438706-7ACE0FFE-180A-461C-9114-A6564ACEB298

Q37438706-A58D812C-2B10-42C0-9328-9E734901FAE3

P304

Q37438706-814C51BE-D871-4D58-A5C5-5D25052CD0D0

P31

Q37438706-CCFA8AD8-615F-42D6-BD89-4786F84D9C4E

P356

Q37438706-1700148B-1775-406B-A062-7735E943B023

P433

Q37438706-30B4733E-DE2A-4087-A090-E77A6954DA0C

P478

Q37438706-5BA33430-100E-4649-BDBC-60F50EFE76FD

P577

Q37438706-0030192E-0B0C-4669-8AFF-F2361762D2B7

P5875

Q37438706-F016C629-D6BB-494B-B08C-80E1D78B6516

P698

Q37438706-D5017149-79C2-4416-8A98-908382DE41C3

P932

Q37438706-6B1CAAC1-8C11-4122-8CF0-7186182F69BA

P356

P1433

Arthritis & Rheumatology

P1476

Efficacy of etanercept in the ...... -label, dose-escalation study.

@en

P2093

Ariel C Bulua

http://www.w3.org/2001/XMLSchema#string

Cheryl H Yarboro

http://www.w3.org/2001/XMLSchema#string

Daniel L Kastner

http://www.w3.org/2001/XMLSchema#string

David Y He

http://www.w3.org/2001/XMLSchema#string

Douglas B Mogul

http://www.w3.org/2001/XMLSchema#string

Harjot Singh

http://www.w3.org/2001/XMLSchema#string

Ivona Aksentijevich

http://www.w3.org/2001/XMLSchema#string

Keith M Hull

http://www.w3.org/2001/XMLSchema#string

Larry R Muenz

http://www.w3.org/2001/XMLSchema#string

Michael M Ward

http://www.w3.org/2001/XMLSchema#string

P2860

Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*)

Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein.

Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS)

The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder.

Long-term clinical profile of children with the low-penetrance R92Q mutation of the TNFRSF1A gene

Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS)

Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab.

Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): c

P304

908-913

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.33416

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51725765

http://www.w3.org/2001/XMLSchema#string

P698

22006113

http://www.w3.org/2001/XMLSchema#string

P932

3882089

http://www.w3.org/2001/XMLSchema#string